On September 30, 2026, Jasper Therapeutics stockholders approved a proposal granting the Board discretion to execute a reverse stock split at any ratio between 1-for-15 and 1-for-35 by December 31, 2026. The vote also authorized an increase in common shares from 490 million to 675 million. Jasper Therapeutics develops therapies for rare diseases.
